These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 32198649)

  • 1. First-in-human phase I study of JPH203, an L-type amino acid transporter 1 inhibitor, in patients with advanced solid tumors.
    Okano N; Naruge D; Kawai K; Kobayashi T; Nagashima F; Endou H; Furuse J
    Invest New Drugs; 2020 Oct; 38(5):1495-1506. PubMed ID: 32198649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarker Analyses in Patients With Advanced Solid Tumors Treated With the LAT1 Inhibitor JPH203.
    Okano N; Hana K; Naruge D; Kawai K; Kobayashi T; Nagashima F; Endou H; Furuse J
    In Vivo; 2020; 34(5):2595-2606. PubMed ID: 32871789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation of the role of transporters on the hepatic elimination of an LAT1 selective inhibitor JPH203.
    Toyoshima J; Kusuhara H; Wempe MF; Endou H; Sugiyama Y
    J Pharm Sci; 2013 Sep; 102(9):3228-38. PubMed ID: 23712732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of l-type amino acid transporter 1 activity as a new therapeutic target for cholangiocarcinoma treatment.
    Yothaisong S; Dokduang H; Anzai N; Hayashi K; Namwat N; Yongvanit P; Sangkhamanon S; Jutabha P; Endou H; Loilome W
    Tumour Biol; 2017 Mar; 39(3):1010428317694545. PubMed ID: 28347255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolism and pharmacokinetic studies of JPH203, an L-amino acid transporter 1 (LAT1) selective compound.
    Wempe MF; Rice PJ; Lightner JW; Jutabha P; Hayashi M; Anzai N; Wakui S; Kusuhara H; Sugiyama Y; Endou H
    Drug Metab Pharmacokinet; 2012; 27(1):155-61. PubMed ID: 21914964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JPH203, an L-type amino acid transporter 1-selective compound, induces apoptosis of YD-38 human oral cancer cells.
    Yun DW; Lee SA; Park MG; Kim JS; Yu SK; Park MR; Kim SG; Oh JS; Kim CS; Kim HJ; Kim JS; Chun HS; Kanai Y; Endou H; Wempe MF; Kim DK
    J Pharmacol Sci; 2014; 124(2):208-17. PubMed ID: 24492461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JPH203, a newly developed anti-cancer drug, shows a preincubation inhibitory effect on L-type amino acid transporter 1 function.
    Okunushi K; Furihata T; Morio H; Muto Y; Higuchi K; Kaneko M; Otsuka Y; Ohno Y; Watanabe Y; Reien Y; Nakagawa K; Sakamoto S; Wakashin H; Shimojo N; Anzai N
    J Pharmacol Sci; 2020 Sep; 144(1):16-22. PubMed ID: 32653341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different Response Profiles of Gastrointestinal Cancer Cells to an L-Type Amino Acid Transporter Inhibitor, JPH203.
    Muto Y; Furihata T; Kaneko M; Higuchi K; Okunushi K; Morio H; Reien Y; Uesato M; Matsubara H; Anzai N
    Anticancer Res; 2019 Jan; 39(1):159-165. PubMed ID: 30591453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. L-type amino acid transporter 1 inhibitor JPH203 prevents the growth of cabazitaxel-resistant prostate cancer by inhibiting cyclin-dependent kinase activity.
    Rii J; Sakamoto S; Mizokami A; Xu M; Fujimoto A; Saito S; Koike H; Tamura T; Arai T; Yamada Y; Goto Y; Sazuka T; Imamura Y; Suzuki K; Kanai Y; Anzai N; Ichikawa T
    Cancer Sci; 2024 Mar; 115(3):937-953. PubMed ID: 38186218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel therapeutic approach for anaplastic thyroid cancer through inhibition of LAT1.
    Enomoto K; Sato F; Tamagawa S; Gunduz M; Onoda N; Uchino S; Muragaki Y; Hotomi M
    Sci Rep; 2019 Oct; 9(1):14616. PubMed ID: 31601917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
    Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
    Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LAT1-specific inhibitor is effective against T cell-mediated allergic skin inflammation.
    Hayashi K; Kaminuma O; Nishimura T; Saeki M; Matsuoka K; Hiroi T; Jutabha P; Iwata Y; Sugiura K; Owada T; Kurasawa K; Okayasu I; Ouchi M; Fujita T; Kanai Y; Endou H; Anzai N
    Allergy; 2020 Feb; 75(2):463-467. PubMed ID: 31403710
    [No Abstract]   [Full Text] [Related]  

  • 13. Induction of CTH expression in response to amino acid starvation confers resistance to anti-LAT1 therapy in MDA-MB-231 cells.
    Yamaga T; Suehiro J; Wada Y; Sakurai H
    Sci Rep; 2022 Jan; 12(1):1021. PubMed ID: 35046465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of continuous infusion 9-aminocamptothecin in patients with advanced solid tumors: 21-day infusion is an active well-tolerated regimen.
    Sewak S; Sorich J; O'Leary J
    Anticancer Drugs; 2006 Jun; 17(5):571-9. PubMed ID: 16702815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses.
    Tamura K; Nakagawa K; Kurata T; Satoh T; Nogami T; Takeda K; Mitsuoka S; Yoshimura N; Kudoh S; Negoro S; Fukuoka M
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):285-93. PubMed ID: 17136542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.
    Heery CR; O'Sullivan-Coyne G; Madan RA; Cordes L; Rajan A; Rauckhorst M; Lamping E; Oyelakin I; Marté JL; Lepone LM; Donahue RN; Grenga I; Cuillerot JM; Neuteboom B; Heydebreck AV; Chin K; Schlom J; Gulley JL
    Lancet Oncol; 2017 May; 18(5):587-598. PubMed ID: 28373007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial.
    Papadopoulos KP; Ben-Ami E; Patnaik A; Trone D; Li J; Demetri GD
    BMC Cancer; 2018 Aug; 18(1):790. PubMed ID: 30081867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of L-type amino acid transporter 1 as a molecular target for prognostic and therapeutic indicators in bladder carcinoma.
    Maimaiti M; Sakamoto S; Yamada Y; Sugiura M; Rii J; Takeuchi N; Imamura Y; Furihata T; Ando K; Higuchi K; Xu M; Sazuka T; Nakamura K; Kaneda A; Kanai Y; Kyprianou N; Ikehara Y; Anzai N; Ichikawa T
    Sci Rep; 2020 Jan; 10(1):1292. PubMed ID: 31992742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteomics and phosphoproteomics reveal key regulators associated with cytostatic effect of amino acid transporter LAT1 inhibitor.
    Okanishi H; Ohgaki R; Okuda S; Endou H; Kanai Y
    Cancer Sci; 2021 Feb; 112(2):871-883. PubMed ID: 33264461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphoproteomics revealed cellular signals immediately responding to disruption of cancer amino acid homeostasis induced by inhibition of L-type amino acid transporter 1.
    Okanishi H; Ohgaki R; Xu M; Endou H; Kanai Y
    Cancer Metab; 2022 Nov; 10(1):18. PubMed ID: 36357940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.